Dyne Therapeutics (NASDAQ:DYN) PT Raised to $52.00 at Morgan Stanley

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) had its price objective lifted by equities research analysts at Morgan Stanley from $48.00 to $52.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Morgan Stanley's price target indicates a potential upside of 18.51% from the company's current price.

Several other analysts also recently issued reports on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. Chardan Capital lifted their price objective on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, May 21st. Jefferies Financial Group increased their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, May 20th. JPMorgan Chase & Co. upped their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an "overweight" rating in a report on Tuesday, July 9th. Finally, Piper Sandler raised their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an "overweight" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $47.89.

Dyne Therapeutics Trading Up 0.5 %

NASDAQ DYN traded up $0.24 during trading on Wednesday, reaching $43.88. The company's stock had a trading volume of 715,536 shares, compared to its average volume of 1,585,487. The business has a 50-day moving average price of $38.35 and a 200-day moving average price of $30.57. Dyne Therapeutics has a 1-year low of $6.40 and a 1-year high of $45.46. The stock has a market capitalization of $3.83 billion, a PE ratio of -11.05 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, analysts expect that Dyne Therapeutics will post -3 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 10,163 shares of the firm's stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company's stock, valued at $5,256,821.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of the business's stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares of the company's stock, valued at approximately $5,256,821.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Richard William Scalzo sold 2,588 shares of the firm's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $73,162.76. Following the completion of the transaction, the senior vice president now directly owns 116,695 shares in the company, valued at approximately $3,298,967.65. The disclosure for this sale can be found here. Insiders sold 202,133 shares of company stock valued at $6,500,387 over the last ninety days. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 5.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company's stock worth $305,000 after purchasing an additional 1,199 shares in the last quarter. Federated Hermes Inc. bought a new position in Dyne Therapeutics during the fourth quarter worth about $4,988,000. Jennison Associates LLC acquired a new position in Dyne Therapeutics in the fourth quarter valued at about $2,698,000. New York State Common Retirement Fund increased its holdings in shares of Dyne Therapeutics by 13.7% in the fourth quarter. New York State Common Retirement Fund now owns 18,592 shares of the company's stock worth $247,000 after acquiring an additional 2,244 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $304,000. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.